Cargando…

Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival

BACKGROUND: Cancer cachexia is a catabolic condition characterized by skeletal muscle wasting, consequent to tumor burden, which negatively impacts tolerance to cancer therapies and contributes to increased mortality. Partly because of the limited knowledge of the underlying mechanisms of cancer cac...

Descripción completa

Detalles Bibliográficos
Autores principales: Judge, Sarah M, Nosacka, Rachel L, Delitto, Daniel, Gerber, Michael H, Cameron, Miles E, Trevino, Jose G, Judge, Andrew R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322478/
https://www.ncbi.nlm.nih.gov/pubmed/30637373
http://dx.doi.org/10.1093/jncics/pky043
_version_ 1783385613630701568
author Judge, Sarah M
Nosacka, Rachel L
Delitto, Daniel
Gerber, Michael H
Cameron, Miles E
Trevino, Jose G
Judge, Andrew R
author_facet Judge, Sarah M
Nosacka, Rachel L
Delitto, Daniel
Gerber, Michael H
Cameron, Miles E
Trevino, Jose G
Judge, Andrew R
author_sort Judge, Sarah M
collection PubMed
description BACKGROUND: Cancer cachexia is a catabolic condition characterized by skeletal muscle wasting, consequent to tumor burden, which negatively impacts tolerance to cancer therapies and contributes to increased mortality. Partly because of the limited knowledge of the underlying mechanisms of cancer cachexia derived from human studies, however, the ability to therapeutically intervene remains elusive. The purpose of the current study was therefore to better define the phenotype of skeletal muscle obtained from patients with pancreatic ductal adenocarcinoma (PDAC), which has one of the highest rates of cachexia. METHODS: Morphological analyses were performed on rectus abdominis muscle biopsies obtained from resectable PDAC patients undergoing tumor resection surgery (N = 20) and from weight-stable non-cancer control subjects undergoing benign abdominal surgery (N = 16). PDAC patients with a body weight loss of greater than 5% during the previous 6 months were considered cachectic (N = 15). Statistical tests were two sided. RESULTS: Skeletal muscle from cachectic PDAC patients had increased collagen content compared with non-cancer control subjects (1.43% vs 9.66%, P = .0004, Dunn test). Across all PDAC patients, collagen content positively correlated with body weight loss (P = .0016, r = 0.672), was increased in patients with lymph node metastasis (P = .007, Mann-Whitney U test), and was associated with survival on univariate (HR = 1.08, 95% confidence interval [CI] = 1.02 to 1.04, P = .008) and multivariable analyses (HR = 1.08, 95% CI = 1.00 to 1.17, P = .038). Cachectic PDAC patients also displayed increased lipid deposition (2.63% vs 5.72%, P = .042), infiltration of CD68+ macrophages (63.6 cells/mm(2) vs 233.8 cells/mm(2), P = .0238), calcium deposition (0.21% vs 2.51%, P = .030), and evidence of deficient cellular quality control mechanisms (Mann-Whitney U test). Transcriptional profiling of all patients supported these findings by identifying gene clusters related to wounding, inflammation, and cellular response to TGF-β upregulated in cachectic PDAC patients compared with non-cancer control subjects. CONCLUSIONS: To our knowledge, this work is the first to demonstrate increased collagen content in cachectic PDAC patients that is associated with poor survival.
format Online
Article
Text
id pubmed-6322478
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-63224782019-01-10 Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival Judge, Sarah M Nosacka, Rachel L Delitto, Daniel Gerber, Michael H Cameron, Miles E Trevino, Jose G Judge, Andrew R JNCI Cancer Spectr Article BACKGROUND: Cancer cachexia is a catabolic condition characterized by skeletal muscle wasting, consequent to tumor burden, which negatively impacts tolerance to cancer therapies and contributes to increased mortality. Partly because of the limited knowledge of the underlying mechanisms of cancer cachexia derived from human studies, however, the ability to therapeutically intervene remains elusive. The purpose of the current study was therefore to better define the phenotype of skeletal muscle obtained from patients with pancreatic ductal adenocarcinoma (PDAC), which has one of the highest rates of cachexia. METHODS: Morphological analyses were performed on rectus abdominis muscle biopsies obtained from resectable PDAC patients undergoing tumor resection surgery (N = 20) and from weight-stable non-cancer control subjects undergoing benign abdominal surgery (N = 16). PDAC patients with a body weight loss of greater than 5% during the previous 6 months were considered cachectic (N = 15). Statistical tests were two sided. RESULTS: Skeletal muscle from cachectic PDAC patients had increased collagen content compared with non-cancer control subjects (1.43% vs 9.66%, P = .0004, Dunn test). Across all PDAC patients, collagen content positively correlated with body weight loss (P = .0016, r = 0.672), was increased in patients with lymph node metastasis (P = .007, Mann-Whitney U test), and was associated with survival on univariate (HR = 1.08, 95% confidence interval [CI] = 1.02 to 1.04, P = .008) and multivariable analyses (HR = 1.08, 95% CI = 1.00 to 1.17, P = .038). Cachectic PDAC patients also displayed increased lipid deposition (2.63% vs 5.72%, P = .042), infiltration of CD68+ macrophages (63.6 cells/mm(2) vs 233.8 cells/mm(2), P = .0238), calcium deposition (0.21% vs 2.51%, P = .030), and evidence of deficient cellular quality control mechanisms (Mann-Whitney U test). Transcriptional profiling of all patients supported these findings by identifying gene clusters related to wounding, inflammation, and cellular response to TGF-β upregulated in cachectic PDAC patients compared with non-cancer control subjects. CONCLUSIONS: To our knowledge, this work is the first to demonstrate increased collagen content in cachectic PDAC patients that is associated with poor survival. Oxford University Press 2019-01-07 /pmc/articles/PMC6322478/ /pubmed/30637373 http://dx.doi.org/10.1093/jncics/pky043 Text en © The Author(s) 2019. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Article
Judge, Sarah M
Nosacka, Rachel L
Delitto, Daniel
Gerber, Michael H
Cameron, Miles E
Trevino, Jose G
Judge, Andrew R
Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival
title Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival
title_full Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival
title_fullStr Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival
title_full_unstemmed Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival
title_short Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival
title_sort skeletal muscle fibrosis in pancreatic cancer patients with respect to survival
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322478/
https://www.ncbi.nlm.nih.gov/pubmed/30637373
http://dx.doi.org/10.1093/jncics/pky043
work_keys_str_mv AT judgesarahm skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival
AT nosackarachell skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival
AT delittodaniel skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival
AT gerbermichaelh skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival
AT cameronmilese skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival
AT trevinojoseg skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival
AT judgeandrewr skeletalmusclefibrosisinpancreaticcancerpatientswithrespecttosurvival